Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. (Q38151563)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Alberto Corsini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Stefano Bellosta

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1681-1709

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

The role of the platelet in the pathogenesis of atherothrombosis

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiogr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacology of emerging novel platelet inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Guidelines on myocardial revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Purinergic signaling and vascular cell proliferation and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pyridine nucleotides and calcium signalling in arterial smooth muscle: from cell physiology to pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

P2 receptor subtypes in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Purine and pyrimidine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Signalling and pharmacological properties of the P2Y receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Identification of the platelet ADP receptor targeted by antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Regulation of platelet functions by P2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are h

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Phosphoinositide 3-kinases and the regulation of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Role of P2Y1 purinoceptor in ADP-induced platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Emerging roles for P2X1 receptors in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Identification of the active metabolite of ticlopidine from rat in vitro metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel resistance: more grist for the mill

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in plat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clinical profile of prasugrel, a novel thienopyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Chronic kidney disease increases risk for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Renal function and outcomes in acute coronary syndrome: impact of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The PLATO trial: do you believe in magic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Intravenous adenosine and dyspnea in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

A risk score to predict bleeding in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel: a case for indication-specific pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Strategy for the treatment of clopidogrel low responsiveness in diabetes mellitus and stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Interaction between statins and clopidogrel: is there anything clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel variability: role of plasma protein binding alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Statin drug interactions and related adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacokinetic basis of the antiplatelet action of prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of platelet inhibition with cangrelor during PCI on ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

P2 receptors: new potential players in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Comparison of differential expression of P2Y₁₂ receptor in culprit coronary plaques in patients with acute myocardial infarction versus stable angina pectoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0126-Z

Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice

21 January 2018

1 reference

12 December 2020

Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis

1 reference

12 December 2020

Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation

1 reference

12 December 2020

Purines 2000: Third International Symposium on Nucleosides and Nucleotides. 9-13 July 2000, Madrid, Spain.

1 reference

12 December 2020

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

1 reference

12 December 2020

The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin

1 reference

12 December 2020

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

1 reference

12 December 2020

Diabetes and mortality following acute coronary syndromes

1 reference

12 December 2020

Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity

1 reference

12 December 2020

Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease

1 reference

12 December 2020

The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics

1 reference

12 December 2020

Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats

1 reference

12 December 2020

Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.

1 reference

12 December 2020

Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel

1 reference

12 December 2020

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

1 reference

12 December 2020

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

12 December 2020

Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo

1 reference

12 December 2020

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

1 reference

12 December 2020

Defective platelet adhesion on vessel subendothelium in uremic patients

1 reference

12 December 2020

Identification and biological activity of the active metabolite of clopidogrel

1 reference

12 December 2020

High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study

1 reference

12 December 2020

Differential effects of anticoagulants on the activation of platelets ex vivo

1 reference

12 December 2020

Ticlopidine: a new platelet aggregation inhibitor.

1 reference

12 December 2020

Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans

1 reference

12 December 2020

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

1 reference

12 December 2020

cAMP is not an important messenger for ADP-induced platelet aggregation

1 reference

12 December 2020

Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis

1 reference

12 December 2020

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis

1 reference

12 December 2020

Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis

1 reference

12 December 2020

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial

1 reference

12 December 2020

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

1 reference

12 December 2020

Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

1 reference

12 December 2020

Impact of P-glycoprotein on clopidogrel absorption

1 reference

12 December 2020

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

1 reference

12 December 2020

Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP

1 reference

12 December 2020

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently

1 reference

12 December 2020

The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.

1 reference

12 December 2020

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans

1 reference

12 December 2020

The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel

1 reference

12 December 2020

Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse

1 reference

12 December 2020

Exploring the ticagrelor-statin interplay in the PLATO trial

1 reference

12 December 2020

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

1 reference

12 December 2020

Nomenclature and classification of purinoceptors.

1 reference

12 December 2020

Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway

1 reference

12 December 2020

Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model

1 reference

12 December 2020

Cangrelor AstraZeneca.

1 reference

12 December 2020

Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy

1 reference

12 December 2020

Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction

1 reference

12 December 2020

Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urge

1 reference

12 December 2020

10.1007/S40265-013-0126-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

1003102907

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24114622%20AND%20SRC:MED&resulttype=core&format=json